研究单位：[1]Xuanwu Hospital,Beijing[2]Beijing Children's Hospital,Capital Medical University Beijing,Beijing,China
研究目的：
This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T) in refractory/relapsed CD19+ B-ALL leukemia patients who have no available curative treatment options, have a limited prognosis with currently available treatments, and were previously treated with a B cell directed cell therapy.
